open access

Ahead of Print
Case report
Submitted: 2021-03-08
Accepted: 2021-05-08
Published online: 2021-10-13
Get Citation

Clinical improvement in Job syndrome following administration of co-trimoxazole, omalizumab and inhaled tobramycin

Ourania Papaioannou1, Theodoros Karampitsakos1, Matthaios Katsaras1, Fotios Sampsonas1, Argyrios Tzouvelekis1
DOI: 10.5603/ARM.a2021.0079
·
Pubmed: 34668182
Affiliations
  1. Department of Respiratory Medicine, University Hospital of Patras, University of Patras, Greece

open access

Ahead of Print
CASE REPORTS
Submitted: 2021-03-08
Accepted: 2021-05-08
Published online: 2021-10-13

Abstract

Established treatment regimens for the autosomal dominant hyperimmunoglobulin E syndrome, denominated Job syndrome, are lacking. Thus, Job syndrome still exerts a dramatic impact on patients’ quality of life. Our aim was to present safety and effectiveness of a regimen including co-trimoxazole, omalizumab and inhaled tobramycin in Job syndrome. A 26-year-old woman diagnosed with Job syndrome since infancy through sequencing revealing G342D mutation in STAT3 gene was initiated in the above mentioned treatment regimen; she was followed for 6 months, and to date, none recurrent pulmonary or skin infection was noticed. Furthermore, a considerable improvement in skin lesions was observed. A combination of anti-IgE and longitudinal use of inhaled antibiotics seems well-founded in Job syndrome.

Abstract

Established treatment regimens for the autosomal dominant hyperimmunoglobulin E syndrome, denominated Job syndrome, are lacking. Thus, Job syndrome still exerts a dramatic impact on patients’ quality of life. Our aim was to present safety and effectiveness of a regimen including co-trimoxazole, omalizumab and inhaled tobramycin in Job syndrome. A 26-year-old woman diagnosed with Job syndrome since infancy through sequencing revealing G342D mutation in STAT3 gene was initiated in the above mentioned treatment regimen; she was followed for 6 months, and to date, none recurrent pulmonary or skin infection was noticed. Furthermore, a considerable improvement in skin lesions was observed. A combination of anti-IgE and longitudinal use of inhaled antibiotics seems well-founded in Job syndrome.

Get Citation

Keywords

Job syndrome, recurrent infections, omalizumab, inhaled antibiotics

About this article
Title

Clinical improvement in Job syndrome following administration of co-trimoxazole, omalizumab and inhaled tobramycin

Journal

Advances in Respiratory Medicine

Issue

Ahead of Print

Article type

Case report

Published online

2021-10-13

DOI

10.5603/ARM.a2021.0079

Pubmed

34668182

Keywords

Job syndrome
recurrent infections
omalizumab
inhaled antibiotics

Authors

Ourania Papaioannou
Theodoros Karampitsakos
Matthaios Katsaras
Fotios Sampsonas
Argyrios Tzouvelekis

References (9)
  1. Hattori K, Hasui M, Masuda K, et al. Successful trimethoprim-sulfamethoxazole therapy in a patient with hyperimmunoglobulin E syndrome. Acta Paediatr. 1993; 82(3): 324–326.
  2. Casale TB. Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis. Am J Respir Crit Care Med. 2001; 164(8 Pt 2): S18–S21.
  3. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001; 108(2): E36.
  4. Alonso-Bello CD, Jiménez-Martínez MD, Vargas-Camaño ME, et al. Partial and transient clinical response to omalizumab in IL-21-induced low STAT3-phosphorylation on hyper-IgE syndrome. Case Reports Immunol. 2019; 2019: 6357256.
  5. Donabedian H, Alling DW, Gallin JI. Levamisole is inferior to placebo in the hyperimmunoglobulin E recurrent-infection (Job's) syndrome. N Engl J Med. 1982; 307(5): 290–292.
  6. Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med. 1999; 340(9): 692–702.
  7. Gernez Y, Freeman AF, Holland SM, et al. Autosomal dominant hyper-IgE syndrome in the USIDNET registry. J Allergy Clin Immunol Pract. 2018; 6(3): 996–1001.
  8. Goel S, Sahu S, Minz RW, et al. STAT3-mediated transcriptional regulation of osteopontin in STAT3 loss-of-function related hyper IgE syndrome. Front Immunol. 2018; 9: 1080.
  9. Hashemi H, Mohebbi M, Mehravaran S, et al. Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings, and treatment modalities. J Res Med Sci. 2017; 22: 53.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl